1. A second-year endocrinology fellow is reviewing the molecular pharmacology of hypothalamic-pituitary signaling. She asks how growth hormone-releasing hormone (GHRH) initiates growth hormone (GH) secretion at the level of the pituitary somatotroph. Which of the following correctly describes the signal transduction cascade activated by GHRH binding to its receptor on somatotrophs?
A) GHRH binds a receptor coupled to Gi, reducing cyclic AMP (cAMP) levels and opening voltage-gated calcium channels to trigger GH exocytosis
B) GHRH binds a seven-transmembrane G protein-coupled receptor (GHRH-R) coupled to Gs, activating adenylyl cyclase and raising cAMP, which activates protein kinase A (PKA) to stimulate GH gene transcription and exocytosis
C) GHRH binds a receptor coupled to Gq/11, activating phospholipase C beta (PLC-beta) and raising inositol trisphosphate (IP3) to mobilize intracellular calcium and trigger GH release
D) GHRH binds a receptor coupled to Gs but signals entirely through protein kinase C (PKC) activation rather than through adenylyl cyclase or cAMP elevation
E) GHRH binds a single-transmembrane tyrosine kinase receptor, autophosphorylating JAK2 (Janus kinase 2) and activating STAT5 (signal transducer and activator of transcription 5) to drive GH gene expression
ANSWER: B
Rationale:
GHRH binds the GHRH-R, a seven-transmembrane GPCR (G protein-coupled receptor) on pituitary somatotrophs that couples exclusively to Gs. Gs activation stimulates adenylyl cyclase, raising intracellular cAMP, which in turn activates PKA (protein kinase A). PKA phosphorylates transcription factors that drive GH gene expression, promotes GH biosynthesis, and ultimately triggers GH exocytosis. The magnitude of each GH pulse is proportional to the amplitude of the preceding GHRH pulse and is gated by simultaneous somatostatin tone.
Option A: Option A is incorrect because Gi-coupled receptors reduce cAMP; Gi signaling describes the somatostatin receptor mechanism, not GHRH-R. The voltage-gated calcium channel relationship to Gi is also inverted.
Option C: Option C is incorrect because Gq/PLC-beta/IP3 signaling describes the ghrelin receptor (GHSR-1a) cascade, not the GHRH-R; GHRH-R couples to Gs, not Gq.
Option D: Option D is incorrect because PKC is a downstream effector of Gq/PLC-beta signaling; the GHRH-R/Gs axis signals through adenylyl cyclase and cAMP/PKA, not through PKC.
Option E: Option E is incorrect because GHRH-R is a GPCR, not a tyrosine kinase receptor; the JAK2-STAT5 pathway describes the GH receptor (GHR) signaling cascade activated by GH itself at peripheral tissues, not the pituitary GHRH-R.
2. An endocrinology attending is explaining why octreotide is effective at suppressing GH hypersecretion in acromegaly. She notes that the pituitary somatotroph expresses multiple somatostatin receptor (SSTR) subtypes but that one subtype is primarily responsible for GH suppression by hypothalamic somatostatin and by somatostatin receptor analogs (SSAs). Which somatostatin receptor subtype is the principal mediator of GH suppression at the pituitary somatotroph?
A) SSTR1 (somatostatin receptor subtype 1), which is expressed at high density on somatotrophs and mediates the dominant inhibitory effect on GH release through strong Gi coupling
B) SSTR3 (somatostatin receptor subtype 3), which has the highest affinity for octreotide among all five receptor subtypes and drives the majority of GH suppression by SSA therapy
C) SSTR4 (somatostatin receptor subtype 4), which is selectively expressed on pituitary somatotrophs and provides tonic inhibition of GH secretion under basal hypothalamic somatostatin tone
D) SSTR2 (somatostatin receptor subtype 2), which is predominantly expressed on pituitary somatotrophs and is the principal receptor through which both endogenous somatostatin and SSTR2-selective SSAs suppress GH secretion
E) SSTR5 (somatostatin receptor subtype 5), which is the dominant pituitary GH-suppressing receptor and is targeted selectively by octreotide to achieve the majority of its clinical GH-lowering effect
ANSWER: D
Rationale:
Pituitary somatotrophs predominantly express SSTR2 and SSTR5 (somatostatin receptor subtypes 2 and 5), with SSTR2 being the principal mediator of GH suppression by endogenous hypothalamic somatostatin and by SSTR2-selective SSAs (somatostatin receptor analogs) such as octreotide and lanreotide. The therapeutic activity of first-generation SSAs is largely attributable to SSTR2 agonism; the addition of SSTR5 targeting accounts for further, incremental GH suppression. All five SSTR subtypes are GPCRs (G protein-coupled receptors) signaling through Gi/Go.
Option A: Option A is incorrect because SSTR1 is not expressed at high density on pituitary somatotrophs and is not the principal mediator of GH suppression; somatostatin receptor analogs have negligible affinity for SSTR1, which is why first-generation SSAs that lack SSTR1 activity still effectively suppress GH.
Option B: Option B is incorrect because octreotide has only moderate affinity for SSTR3 (somatostatin receptor subtype 3) and this subtype does not drive the majority of GH suppression; the dominant octreotide binding sites are SSTR2 and SSTR5.
Option C: Option C is incorrect because SSTR4 is expressed at very low levels in the pituitary and does not play a significant role in GH suppression; current SSAs have negligible affinity for SSTR4.
Option E: Option E is incorrect because while SSTR5 contributes to GH suppression and is targeted by pasireotide (pan-SSTR agonist) at approximately 40-fold higher affinity than octreotide, it is not the dominant receptor for endogenous somatostatin-mediated GH suppression; SSTR2 holds that primary role at the somatotroph.
3. A pharmacology student asks about the signal transduction pathway used by ghrelin to stimulate growth hormone (GH) secretion from pituitary somatotrophs. Ghrelin is an acylated peptide that must be octanoylated at serine-3 to be biologically active. Which of the following correctly describes the receptor and intracellular signaling cascade through which ghrelin stimulates GH release?
A) Ghrelin binds the growth hormone secretagogue receptor type 1a (GHSR-1a), a GPCR (G protein-coupled receptor) coupled to Gq/11, activating phospholipase C beta (PLC-beta) and generating IP3 (inositol trisphosphate) and DAG (diacylglycerol), which mobilize intracellular calcium and activate protein kinase C (PKC) to potentiate GH release
B) Ghrelin binds GHSR-1a coupled to Gs, raising cyclic AMP (cAMP) through adenylyl cyclase activation and thereby stimulating GH exocytosis through a protein kinase A (PKA)-dependent mechanism
C) Ghrelin binds a single-transmembrane receptor that activates JAK2 (Janus kinase 2) directly, stimulating STAT5 (signal transducer and activator of transcription 5) phosphorylation and GH gene transcription in somatotrophs
D) Ghrelin binds SSTR2 (somatostatin receptor subtype 2) in competition with somatostatin, and displacing somatostatin from this receptor disinhibits adenylyl cyclase to release GH
E) Ghrelin binds the GHRH receptor (GHRH-R), acting as a partial agonist at the same receptor as growth hormone-releasing hormone (GHRH) but producing a smaller cAMP elevation and a lower-amplitude GH pulse
ANSWER: A
Rationale:
Ghrelin must be acylated at serine-3 by ghrelin O-acyltransferase (GOAT) for biological activity at its receptor. The active receptor is GHSR-1a (growth hormone secretagogue receptor type 1a), which is a GPCR coupled to Gq/11 — not Gs. Gq activation stimulates PLC-beta (phospholipase C beta), which cleaves PIP2 into IP3 (inositol trisphosphate) and DAG (diacylglycerol). IP3 mobilizes calcium from intracellular stores, and DAG activates PKC (protein kinase C); together these signals potentiate GH release. Ghrelin acts synergistically with GHRH to amplify GH pulse amplitude: neither signal alone produces the full pulsatile response. Macimorelin, a synthetic GHSR-1a agonist used diagnostically for adult GH deficiency, shares this receptor and signaling pathway.
Option B: Option B is incorrect because GHSR-1a couples to Gq/11, not Gs; Gs/cAMP/PKA is the GHRH-R pathway, not the ghrelin receptor pathway.
Option C: Option C is incorrect because GHSR-1a is a GPCR, not a single-transmembrane receptor; the JAK2-STAT5 pathway describes GH receptor (GHR) signaling at peripheral target tissues, not pituitary ghrelin receptor signaling.
Option D: Option D is incorrect because ghrelin does not bind SSTR2; SSTR2 is the principal pituitary somatostatin receptor and is bound by somatostatin and its analogs, not by ghrelin; the two systems are distinct.
Option E: Option E is incorrect because ghrelin and GHRH act through entirely different receptors — GHSR-1a and GHRH-R respectively; ghrelin is not a partial agonist at GHRH-R.
4. A medical resident is reviewing the pharmacology of somatostatin receptor analogs (SSAs). She wants to understand the receptor binding profile of octreotide compared with the five somatostatin receptor subtypes (SSTR1 through SSTR5) in order to predict both its therapeutic activity and its adverse effect profile. Which of the following correctly describes octreotide's receptor selectivity?
A) Octreotide binds all five SSTR subtypes with approximately equal affinity, making it a pan-SSTR agonist with the broadest possible spectrum of GH, insulin, and glucagon suppression
B) Octreotide binds SSTR1 and SSTR4 with the highest affinity among the five subtypes, and its GH-suppressing activity in acromegaly depends primarily on SSTR4 agonism at the pituitary somatotroph
C) Octreotide has high binding affinity for SSTR2 and SSTR5 and moderate affinity for SSTR3, with negligible affinity for SSTR1 and SSTR4; its dominant GH-suppressing and insulin/glucagon-suppressing effects derive primarily from SSTR2 and SSTR5 agonism
D) Octreotide is a SSTR2-only selective agent with no measurable affinity for any other somatostatin receptor subtype, which explains why it suppresses GH but does not affect insulin or glucagon secretion in clinical practice
E) Octreotide binds SSTR3 and SSTR5 with high affinity but has low SSTR2 affinity, distinguishing it mechanistically from lanreotide and explaining its superior GH-suppressing potency in acromegaly compared with lanreotide
ANSWER: C
Rationale:
Octreotide is a synthetic octapeptide somatostatin analog with high binding affinity for SSTR2 (somatostatin receptor subtype 2) and SSTR5 (somatostatin receptor subtype 5), and moderate affinity for SSTR3 (subtype 3). It has negligible affinity for SSTR1 (subtype 1) and SSTR4 (subtype 4). At the pituitary somatotroph, SSTR2 is the principal receptor mediating GH suppression, with SSTR5 contributing additional inhibition. At pancreatic beta and delta cells, SSTR2 and SSTR5 expression mediates suppression of both insulin and glucagon secretion; this is the mechanistic basis for the glycemic dysregulation observed with SSA therapy, including both hypoglycemia (reduced glucagon) and hyperglycemia (reduced insulin secretion).
Option A: Option A is incorrect because octreotide is not a pan-SSTR agonist; equal affinity across all five subtypes describes no currently approved SSA. Pasireotide binds SSTR1, SSTR2, SSTR3, and SSTR5, but with substantially higher affinity for SSTR5 than octreotide, not equal affinity.
Option B: Option B is incorrect because octreotide has negligible affinity for SSTR1 and SSTR4; these subtypes are not clinically relevant targets for octreotide, and SSTR4 agonism does not drive octreotide's GH-suppressing activity.
Option D: Option D is incorrect because octreotide also binds SSTR5 with high affinity and SSTR3 with moderate affinity; this multi-subtype activity accounts for the insulin and glucagon suppression observed clinically, contradicting the claim that it does not affect pancreatic secretion.
Option E: Option E is incorrect because octreotide has high affinity for SSTR2, not low; and the claim that its GH-suppressing potency exceeds lanreotide is not supported — head-to-head studies show equivalent rates of GH and IGF-1 normalization for octreotide LAR and lanreotide Autogel in acromegaly.
5. A patient with acromegaly is being transitioned from subcutaneous (SC) octreotide three times daily to the long-acting release (LAR) depot formulation, octreotide LAR, given by intramuscular (IM) injection every 28 days. The endocrinologist explains to the resident that an important pharmacokinetic feature of octreotide LAR affects how the transition must be managed. Which of the following correctly describes this pharmacokinetic feature and its clinical implication?
A) Octreotide LAR achieves therapeutic plasma concentrations within 24 hours of the first IM injection because the poly(lactic-co-glycolic acid) (PLGA) microspheres dissolve rapidly; SC octreotide should be discontinued the day before the first LAR dose to avoid supratherapeutic levels
B) Octreotide LAR produces an initial burst of drug release in the first 48 hours following IM injection, achieving supratherapeutic octreotide levels that require a dose reduction in the first cycle; the standard 20 mg dose is reserved for months two and three
C) Octreotide LAR achieves stable plasma concentrations after a single injection and does not require bridging therapy, but the dose must be doubled in the first cycle to saturate the microsphere polymer matrix before controlled release begins
D) Octreotide LAR has a 4-week loading period during which the drug is inactive because the microspheres require enzymatic degradation before octreotide is released; no GH suppression occurs during this interval regardless of bridging therapy
E) Octreotide LAR requires approximately 14 days after the first IM injection before therapeutic plasma concentrations are reached because octreotide release from the PLGA microspheres is delayed; SC octreotide bridging is continued during this interval to maintain GH suppression
ANSWER: E
Rationale:
Octreotide LAR (Sandostatin LAR) consists of microspheres of poly(lactic-co-glycolic acid) (PLGA) polymer encapsulating octreotide for intramuscular injection. After IM administration, there is an initial delay of approximately 14 days before the polymer matrix begins releasing drug at therapeutic concentrations. During this lag phase, plasma octreotide levels are subtherapeutic, and GH suppression in acromegaly would be lost if the patient's short-acting SC octreotide were discontinued at the time of the first LAR injection. The standard management is to continue SC octreotide (three-times-daily dosing) for the first 14 days following the first LAR injection as bridging therapy, then discontinue the SC drug. This pharmacokinetic feature distinguishes octreotide LAR from lanreotide Autogel, which achieves therapeutic concentrations without a loading lag because of its gel-depot diffusion mechanism.
Option A: Option A is incorrect because octreotide LAR does not achieve therapeutic levels within 24 hours; rapid initial dissolution is not a characteristic of the PLGA microsphere system, and the concern is subtherapeutic levels, not supratherapeutic ones.
Option B: Option B is incorrect because there is no early supratherapeutic burst with octreotide LAR; the pharmacokinetics show delayed, not accelerated, early release; the standard starting dose is 20 mg every 28 days without any dose reduction in cycle 1.
Option C: Option C is incorrect because octreotide LAR does not achieve stable concentrations from a single injection without bridging; the 14-day lag is well established and SC bridging is standard practice for this reason.
Option D: Option D is incorrect because the lag is approximately 14 days, not 4 weeks, and octreotide release does begin during the lag period — it simply remains below therapeutic thresholds for approximately two weeks; SC bridging does maintain GH suppression during this interval.
6. An endocrinology fellow is counseling a newly diagnosed acromegaly patient who requires medical therapy after incomplete surgical resection. The fellow explains the difference between octreotide LAR and lanreotide Autogel in terms of their depot formulations and pharmacokinetics. Which of the following correctly describes the pharmacokinetic feature that distinguishes lanreotide Autogel from octreotide LAR with respect to onset of therapeutic drug levels?
A) Lanreotide Autogel uses a PLGA (poly(lactic-co-glycolic acid)) microsphere system similar to octreotide LAR but with smaller particle size, which accelerates polymer degradation and reduces the lag to therapeutic levels from 14 days to approximately 5 days
B) Lanreotide Autogel is a high-viscosity aqueous gel that releases lanreotide by diffusion from a deep subcutaneous (SC) depot; because diffusion begins immediately after injection, therapeutic plasma concentrations are achieved without the 14-day loading lag required by octreotide LAR microspheres
C) Lanreotide Autogel achieves faster onset than octreotide LAR because it is administered intravenously rather than subcutaneously, bypassing the absorption step and producing immediate GH suppression from the first dose
D) Lanreotide Autogel is a prodrug formulation that undergoes rapid hepatic first-pass conversion to the active lanreotide metabolite, producing peak plasma activity within 6 hours of injection and eliminating the need for bridging therapy
E) Lanreotide Autogel and octreotide LAR have identical pharmacokinetic profiles because both use polymer-based depot systems; any perceived clinical difference in onset is attributable to differing SSTR2 receptor affinities rather than formulation
ANSWER: B
Rationale:
Lanreotide Autogel (Somatuline Depot) is formulated as a high-viscosity aqueous gel for deep subcutaneous injection using a pre-filled syringe. Unlike octreotide LAR, which uses PLGA (poly(lactic-co-glycolic acid)) microspheres that require approximately 14 days before releasing drug at therapeutic concentrations, lanreotide Autogel forms a subcutaneous depot from which lanreotide is released by simple diffusion, beginning immediately after injection. This mechanism means that lanreotide Autogel achieves therapeutic plasma concentrations without a loading lag, and SC bridging therapy is not required when initiating treatment. Both formulations are administered every 28 days (with an option for every 6 or 8 weeks in patients who achieve biochemical control on lanreotide), and both achieve equivalent rates of GH and IGF-1 normalization in comparative studies.
Option A: Option A is incorrect because lanreotide Autogel does not use a PLGA microsphere system; the gel-diffusion mechanism is the critical pharmacokinetic distinction, not particle size variation within a microsphere system.
Option C: Option C is incorrect because lanreotide Autogel is administered by deep subcutaneous injection, not intravenously; the route is SC, not IV, and this is a significant distinction from octreotide LAR, which is given by IM injection.
Option D: Option D is incorrect because lanreotide Autogel is not a prodrug and does not undergo hepatic first-pass conversion; SSAs are administered parenterally specifically to avoid first-pass metabolism, and lanreotide is the active compound in the formulation.
Option E: Option E is incorrect because the formulations use fundamentally different depot systems — PLGA microspheres for octreotide LAR versus aqueous gel for lanreotide Autogel — producing different onset kinetics; the pharmacokinetic difference is real and not explained by receptor affinity differences.
7. A patient with acromegaly has failed to achieve biochemical control on maximum-dose octreotide LAR and is being considered for pasireotide LAR. The endocrinologist explains that pasireotide has a fundamentally different receptor binding profile from octreotide that accounts for its higher efficacy in refractory cases. Which of the following correctly describes the key pharmacological distinction between pasireotide and octreotide in terms of somatostatin receptor (SSTR) binding?
A) Pasireotide is a SSTR2-selective agonist with approximately 10-fold higher affinity for SSTR2 than octreotide, and its superior efficacy in octreotide-refractory acromegaly results entirely from stronger SSTR2 agonism at residual receptor sites
B) Pasireotide binds SSTR1, SSTR2, SSTR3, and SSTR5 (a pan-SSTR agonist profile), with its SSTR2 affinity approximately 40-fold higher than that of octreotide, making it the most potent SSTR2 agonist currently in clinical use
C) Pasireotide is identical to octreotide in its SSTR2 and SSTR5 affinity but additionally binds SSTR4 with high affinity, and it is the SSTR4 component that drives the additional GH suppression seen in octreotide-refractory patients
D) Pasireotide is a pan-SSTR agonist binding SSTR1, SSTR2, SSTR3, and SSTR5 with high affinity; its SSTR5 affinity is approximately 40-fold higher than that of octreotide, and this enhanced SSTR5 activity combined with SSTR1 agonism provides additional GH suppression beyond what SSTR2-selective agents achieve
E) Pasireotide selectively binds SSTR5 only, achieving GH suppression through a receptor entirely distinct from that used by octreotide; because the two drugs act through non-overlapping receptors, there is no cross-tachyphylaxis between them
ANSWER: D
Rationale:
Pasireotide is a cyclohexapeptide somatostatin receptor analog (SSA) with a distinctly broader receptor binding profile than octreotide or lanreotide. It binds SSTR1, SSTR2, SSTR3, and SSTR5 with high affinity and is therefore designated a pan-SSTR agonist (pan-somatostatin receptor agonist). The critical pharmacological distinction is at SSTR5: pasireotide's SSTR5 affinity is approximately 40-fold higher than that of octreotide, and its SSTR1 activity adds further suppression not achievable by SSTR2-selective agents. In the PAOLA (Pasireotide versus Octreotide LAR Acromegaly) trial, pasireotide LAR 40 mg and 60 mg monthly produced biochemical control in 31 to 38% of patients incompletely controlled by first-generation SSAs, compared with 19% for switching to the alternative SSTR2-selective agent. The expanded receptor coverage, not merely stronger SSTR2 binding, is the mechanism underlying this incremental efficacy.
Option A: Option A is incorrect because pasireotide's advantage is not attributable to stronger SSTR2 affinity; rather, the key distinction is its additional high-affinity SSTR5 and SSTR1 binding; the claim that SSTR2 affinity is 40-fold higher than octreotide's inverts the correct finding, which concerns SSTR5, not SSTR2.
Option B: Option B is incorrect because it correctly identifies the pan-SSTR profile but misassigns the 40-fold affinity advantage to SSTR2; it is SSTR5, not SSTR2, at which pasireotide's affinity is approximately 40-fold greater than octreotide's.
Option C: Option C is incorrect because pasireotide does not bind SSTR4 with high affinity; SSTR4 is not part of its clinical pharmacological profile and does not explain its efficacy in refractory acromegaly.
Option E: Option E is incorrect because pasireotide is not SSTR5-selective; it binds multiple subtypes including SSTR2, and its receptor profile substantially overlaps with octreotide, not the opposite.
8. A patient starting pasireotide LAR for acromegaly develops significant hyperglycemia within 6 weeks of initiating therapy. Her endocrinologist explains that the hyperglycemia associated with pasireotide is mechanistically distinct from that caused by first-generation somatostatin receptor analogs (SSAs) and has specific implications for which antidiabetic agents are likely to be effective. Which of the following correctly describes the mechanism of pasireotide-induced hyperglycemia?
A) Pasireotide's high SSTR5 affinity causes profound suppression of both insulin secretion from pancreatic beta cells and incretin hormone release (GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)) from intestinal cells; the combination of reduced insulin secretory drive and absent incretin amplification makes GLP-1 receptor agonists and insulin the preferred treatment options
B) Pasireotide causes hyperglycemia exclusively by increasing hepatic glucose output through glucagon hypersecretion; because insulin secretion is preserved, insulin sensitizers such as metformin are the most effective agents for managing this complication
C) Pasireotide suppresses insulin secretion only by blocking SSTR2 on pancreatic beta cells; the mechanism is identical to that of octreotide and lanreotide, and standard antidiabetic regimens including metformin, SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors), and DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) are equally effective
D) Pasireotide causes hyperglycemia by inducing severe insulin resistance at the hepatic and peripheral level through JAK2-STAT5 (Janus kinase 2-signal transducer and activator of transcription 5) pathway interference; insulin sensitizers are first-line because the secretory defect is minor
E) Pasireotide suppresses glucagon secretion more potently than it suppresses insulin secretion; the net effect is hypoglycemia in fasting patients and hyperglycemia only postprandially, which is best managed with short-acting prandial insulin alone
ANSWER: A
Rationale:
Pasireotide's metabolic liability substantially exceeds that of first-generation SSAs because of its high SSTR5 affinity. SSTR5 is expressed on pancreatic beta cells and suppresses insulin secretion; pasireotide's 40-fold greater SSTR5 affinity compared with octreotide translates into more profound insulin secretory suppression. In addition, SSTR5 is expressed on intestinal L cells and K cells, and pasireotide suppresses GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) incretin release. The clinical consequence is that hyperglycemia occurs in approximately 57 to 73% of pasireotide-treated patients, compared with 10 to 20% for SSTR2-selective agents. Critically, agents that depend on incretin action — DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) — are largely ineffective because pasireotide suppresses the very incretins these agents require for their mechanism of action. Metformin and SGLT2 inhibitors address insulin resistance and glucosuria but do not restore insulin secretion. GLP-1 receptor agonists bypass the suppressed endogenous incretin system by acting directly on the GLP-1 receptor, and insulin directly replaces the suppressed secretory drive; both are preferred.
Option B: Option B is incorrect because pasireotide does not cause hyperglycemia primarily through glucagon hypersecretion; it actually suppresses glucagon as well as insulin, and the dominant mechanism is reduced insulin and incretin secretion, not glucagon excess.
Option C: Option C is incorrect because pasireotide's mechanism is not identical to octreotide's; its high SSTR5 affinity with additional incretin suppression makes DPP-4 inhibitors and metformin substantially less effective than they would be for octreotide-related hyperglycemia.
Option D: Option D is incorrect because the primary mechanism is a secretory defect, not insulin resistance; JAK2-STAT5 interference is the mechanism by which pegvisomant prevents GH receptor signaling, not a feature of pasireotide's glycemic effects.
Option E: Option E is incorrect because pasireotide does not preferentially suppress glucagon over insulin; it suppresses both, with insulin secretion being more severely impaired relative to the overall hyperglycemic net effect; the clinical result is predominantly fasting and postprandial hyperglycemia, not hypoglycemia.
9. An acromegaly patient on pasireotide LAR develops a fasting glucose of 185 mg/dL. Her primary care physician proposes starting sitagliptin, a DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor), because the patient has a preference for oral agents. The endocrinologist objects and recommends a different drug class instead. What is the pharmacological reason that DPP-4 inhibitors are not an appropriate first-line choice for pasireotide-induced hyperglycemia?
A) DPP-4 inhibitors are contraindicated in patients receiving somatostatin receptor analogs (SSAs) because they competitively inhibit the same dipeptidyl peptidase enzyme that inactivates octreotide and lanreotide, raising SSA plasma levels and increasing GH suppression to toxic levels
B) DPP-4 inhibitors require functioning pancreatic beta cells to work; because pasireotide causes complete pancreatic beta cell apoptosis within 8 weeks, there is no viable beta cell mass left to respond to the incretin signal amplified by DPP-4 inhibition
C) DPP-4 inhibitors work by preventing the enzymatic degradation of endogenous GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide); because pasireotide suppresses incretin secretion at the intestinal source through SSTR5 agonism, there is insufficient endogenous incretin available for DPP-4 inhibitors to preserve, making their mechanism ineffective
D) DPP-4 inhibitors are cleared exclusively by the kidney and are contraindicated in patients with GFR (glomerular filtration rate) below 60 mL/min; acromegaly universally causes renal impairment sufficient to preclude their use
E) DPP-4 inhibitors are first-line for pasireotide hyperglycemia but are no more effective than metformin; the endocrinologist's preference for GLP-1 receptor agonists reflects institutional bias rather than a pharmacological distinction
ANSWER: C
Rationale:
DPP-4 inhibitors such as sitagliptin work by inhibiting the enzyme dipeptidyl peptidase-4, which rapidly degrades the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By preventing incretin degradation, DPP-4 inhibitors raise postprandial GLP-1 and GIP levels, which then stimulate glucose-dependent insulin secretion from beta cells. This mechanism depends entirely on the availability of endogenous incretin hormones secreted from intestinal L cells and K cells. Pasireotide suppresses incretin secretion at the source through its high-affinity SSTR5 agonism at intestinal endocrine cells; if GLP-1 and GIP are not being secreted, there is nothing for DPP-4 inhibitors to preserve. As a result, DPP-4 inhibitors are largely ineffective in pasireotide-treated patients. GLP-1 receptor agonists bypass this problem by acting directly on the GLP-1 receptor independently of endogenous GLP-1; and insulin directly replaces the lost secretory drive.
Option A: Option A is incorrect because there is no pharmacokinetic interaction between DPP-4 inhibitors and SSAs through the DPP-4 enzyme; the enzyme that degrades incretins is not the enzyme responsible for inactivating octreotide or lanreotide, and DPP-4 inhibitors do not raise SSA plasma levels.
Option B: Option B is incorrect because pasireotide does not cause beta cell apoptosis; it causes functional suppression of insulin secretion through receptor-mediated signaling, which is reversible on drug discontinuation; complete beta cell destruction is not a feature of SSA therapy.
Option D: Option D is incorrect because although some DPP-4 inhibitors require dose reduction in renal impairment, this is not a universal absolute contraindication in acromegaly patients and does not explain the pharmacological rationale for avoiding this drug class in pasireotide-treated patients.
Option E: Option E is incorrect because GLP-1 receptor agonists are preferred over DPP-4 inhibitors for a specific mechanistic reason — not institutional bias — as explained; the pharmacological distinction between these classes in the context of pasireotide therapy is well established.
10. A 47-year-old patient with acromegaly has been on long-term octreotide LAR for 18 months. He presents with right upper quadrant pain and an ultrasound reveals multiple gallstones. His gastroenterologist asks the treating endocrinologist whether this is related to the octreotide therapy. Which of the following correctly describes the mechanism by which somatostatin receptor analogs (SSAs) promote gallstone formation, and the expected incidence of this complication?
A) SSAs cause gallstone formation by inhibiting hepatic bile acid synthesis through SSTR3 agonism at hepatocytes, leading to supersaturation of bile with cholesterol; this complication occurs in approximately 5% of patients on long-term therapy
B) SSAs cause gallstones by stimulating gallbladder contractility and accelerating bile flow through the biliary tree, causing rapid crystallization of cholesterol in the common bile duct rather than the gallbladder itself
C) SSAs cause cholelithiasis by directly precipitating calcium bilirubinate within the gallbladder lumen through an osmotic mechanism; this complication is confined to patients with pre-existing biliary tract disease and does not occur in patients with previously normal gallbladder function
D) SSAs cause gallstone formation by markedly increasing biliary cholesterol secretion from hepatocytes through CYP7A1 (cytochrome P450 7A1) induction, shifting the bile acid to cholesterol ratio; incidence is approximately 40 to 50% with long-term use
E) SSAs inhibit gallbladder contractility by suppressing cholecystokinin (CCK) release; reduced gallbladder emptying leads to bile stasis and stone formation; symptomatic cholelithiasis develops in approximately 20 to 30% of patients on long-term SSA therapy, though only 1 to 2% develop cholecystitis requiring cholecystectomy
ANSWER: E
Rationale:
All somatostatin receptor analogs — octreotide, lanreotide, and pasireotide — inhibit gallbladder contractility through suppression of cholecystokinin (CCK) release. CCK is the primary hormonal stimulus for postprandial gallbladder contraction; without CCK-driven emptying, bile stagnates in the gallbladder, increasing the concentration of biliary cholesterol and bile salts and promoting crystallization and stone formation. The incidence of gallstone development on long-term SSA therapy is approximately 20 to 30%, making it one of the most common long-term adverse effects. The large majority of these cases are asymptomatic; only approximately 1 to 2% of treated patients develop clinically significant acute cholecystitis requiring cholecystectomy. Ursodeoxycholic acid prophylaxis is not routinely recommended unless the patient has additional biliary risk factors.
Option A: Option A is incorrect because SSAs do not inhibit hepatic bile acid synthesis through SSTR3 at hepatocytes; the mechanism is reduced gallbladder motility from CCK suppression, not bile acid synthesis inhibition; and the incidence is substantially higher than 5%.
Option B: Option B is incorrect because SSAs reduce, not stimulate, gallbladder contractility; the pathophysiology of SSA-associated cholelithiasis is bile stasis from reduced CCK-mediated emptying, the opposite of accelerated bile flow.
Option C: Option C is incorrect because SSA-associated cholelithiasis is not confined to patients with pre-existing biliary disease and does not arise through an osmotic calcium bilirubinate precipitation mechanism; it occurs in previously normal gallbladders and the mechanism involves bile stasis and cholesterol supersaturation.
Option D: Option D is incorrect because SSAs do not cause cholelithiasis through CYP7A1 induction or increased biliary cholesterol secretion; their primary hepatic interaction involves bile stasis downstream of CCK suppression; and the 40 to 50% incidence figure cited substantially overstates the established rate.
11. A 52-year-old man with HIV (human immunodeficiency virus) on long-term antiretroviral therapy presents with progressive central abdominal adiposity. Imaging confirms marked visceral adipose tissue (VAT) accumulation consistent with antiretroviral therapy-associated lipodystrophy. His provider considers pharmacological intervention to address the visceral fat excess. Which of the following growth hormone axis agents is FDA (U.S. Food and Drug Administration)-approved specifically for this indication, and what is its mechanism of action?
A) Sermorelin, a synthetic 29-amino acid GHRH (growth hormone-releasing hormone) analog, is approved for reducing VAT in HIV-associated lipodystrophy; it acts by stimulating endogenous GH (growth hormone) release from an intact pituitary somatotroph pool
B) Tesamorelin, a synthetic GHRH analog with a trans-3-hexenoic acid modification at the N-terminus that protects it from DPP-4 (dipeptidyl peptidase-4) cleavage, is FDA-approved for reducing excess VAT in HIV-infected patients with antiretroviral therapy-associated lipodystrophy; it stimulates endogenous GH release rather than replacing GH directly
C) Somatropin (recombinant human GH) is FDA-approved at a specific low-dose regimen for reducing VAT in HIV-associated lipodystrophy through direct replacement of GH deficiency caused by antiretroviral agents
D) Macimorelin, an oral ghrelin receptor (GHSR-1a) agonist, is FDA-approved for managing VAT accumulation in HIV-associated lipodystrophy by stimulating pulsatile GH release that preferentially mobilizes visceral fat
E) Pegvisomant, a GH receptor antagonist, is used to reduce VAT in HIV-associated lipodystrophy by blocking IGF-1 (insulin-like growth factor-1)-driven visceral fat hypertrophy through downstream GHR (GH receptor) antagonism
ANSWER: B
Rationale:
Tesamorelin (TH9507) is a synthetic analog of the full 44-amino acid sequence of native GHRH, stabilized by conjugation with a trans-3-hexenoic acid group at the N-terminus, which protects the molecule from enzymatic cleavage by DPP-4 (dipeptidyl peptidase-4). This modification substantially extends its half-life compared with native GHRH. Tesamorelin is the only growth hormone axis agent with FDA approval specifically for the reduction of excess visceral adipose tissue in HIV-infected patients with antiretroviral therapy-associated lipodystrophy, at a dose of 2 mg SC (subcutaneous) daily. It stimulates endogenous GH release from pituitary somatotrophs rather than replacing GH directly, preserving pulsatile GH secretion and negative feedback. Pivotal trials demonstrated approximately 15 to 20% reduction in trunk fat over 26 weeks with concurrent lipid improvements. Like all GHRH analogs, it requires an intact pituitary somatotroph pool for efficacy.
Option A: Option A is incorrect because sermorelin is not FDA-approved for HIV-associated lipodystrophy; it is used as a diagnostic provocative agent for GH secretory reserve in children and has been largely supplanted by direct somatropin replacement in adults; its use in lipodystrophy is off-label at best.
Option C: Option C is incorrect because somatropin is not FDA-approved at any dosing regimen specifically for HIV-associated lipodystrophy-related VAT reduction; the approved indication for this metabolic complication belongs to tesamorelin, not direct GH replacement.
Option D: Option D is incorrect because macimorelin is FDA-approved only as a diagnostic agent for adult GH deficiency testing, not as a therapeutic agent for VAT reduction in any indication.
Option E: Option E is incorrect because pegvisomant is a GH receptor antagonist approved for acromegaly; it does not reduce VAT in HIV lipodystrophy and would be pharmacologically counterproductive — blocking GH receptor activity would worsen, not improve, the body composition abnormalities associated with suppressed GH pulsatility in this condition.
12. An HIV-infected patient on long-term antiretroviral therapy is being evaluated for tesamorelin therapy to address significant visceral adipose tissue accumulation from lipodystrophy. During the pre-treatment evaluation, the provider identifies a clinical finding that constitutes a contraindication to tesamorelin. Which of the following represents the contraindication specific to tesamorelin's mechanism of action?
A) A history of type 2 diabetes mellitus with HbA1c (hemoglobin A1c) currently at 7.4%, because tesamorelin's stimulation of GH (growth hormone) release will cause unmanageable glucose intolerance that cannot be controlled with oral antidiabetic agents
B) A CD4 count below 200 cells per microliter, because tesamorelin requires functional CD4 lymphocytes to stimulate hepatic IGF-1 (insulin-like growth factor-1) production and is ineffective at CD4 counts below this threshold
C) Concurrent use of a protease inhibitor-based antiretroviral regimen, because protease inhibitors strongly inhibit CYP3A4 (cytochrome P450 3A4) and prevent tesamorelin's metabolic activation to its biologically active form
D) Active malignancy, because tesamorelin stimulates endogenous GH release and raises circulating IGF-1 levels, and IGF-1 has growth-promoting and anti-apoptotic effects at tumor cells; the risk of accelerating tumor growth makes active malignancy a contraindication to tesamorelin therapy
E) A baseline QTc interval exceeding 450 milliseconds, because tesamorelin causes dose-dependent QT prolongation through GHRH receptor (GHRH-R) agonism at cardiac tissue, and patients with prolonged baseline QTc are at risk for torsades de pointes
ANSWER: D
Rationale:
Tesamorelin stimulates endogenous GH release from pituitary somatotrophs, which in turn drives hepatic IGF-1 (insulin-like growth factor-1) production. IGF-1 has well-established growth-promoting and anti-apoptotic effects at the cellular level, including actions on tumor cells. Because of the risk that elevated IGF-1 could accelerate the growth of existing tumors, active malignancy is a contraindication to tesamorelin therapy. This contraindication is shared with somatropin (recombinant GH replacement) and reflects the fundamental oncological concern with any agent that raises IGF-1. Patients must be evaluated for current malignancy before initiating tesamorelin, and the drug should not be restarted if a malignancy develops during therapy.
Option A: Option A is incorrect because pre-existing type 2 diabetes with HbA1c at 7.4% is not an absolute contraindication to tesamorelin; glucose metabolism should be monitored during therapy, and worsening of glucose tolerance is an expected adverse effect that can be managed, but it does not constitute a contraindication at this level of control.
Option B: Option B is incorrect because tesamorelin's mechanism of action does not require CD4 lymphocytes for IGF-1 production; hepatic IGF-1 synthesis is driven by GH receptor signaling in hepatocytes, which is independent of CD4 lymphocyte count; no CD4 threshold governs tesamorelin efficacy.
Option C: Option C is incorrect because tesamorelin is not metabolically activated by CYP3A4; it is a peptide analog that acts directly at the GHRH receptor and is inactivated by proteolytic cleavage, not by CYP enzymes; the N-terminal modification protects it from DPP-4, not from CYP3A4.
Option E: Option E is incorrect because QT prolongation is a known safety concern with macimorelin, not with tesamorelin; QTc evaluation before testing is a requirement for the macimorelin stimulation test, and this safety consideration should not be transposed onto tesamorelin.
13. An endocrinologist is evaluating a 44-year-old patient with suspected adult GH (growth hormone) deficiency following pituitary surgery for a non-functioning adenoma. She considers pharmacological stimulation testing to confirm the diagnosis. Which of the following correctly describes the mechanism and diagnostic parameters of macimorelin as a GH stimulation agent?
A) Macimorelin is an orally bioavailable, small molecule agonist at the ghrelin receptor (GHSR-1a (growth hormone secretagogue receptor type 1a)); administered as a single oral dose of 0.5 mg/kg after an overnight fast, it stimulates GH secretion, and a peak GH below 2.8 ng/mL on a standardized immunoassay establishes the diagnosis of adult GH deficiency
B) Macimorelin is an injectable synthetic GHRH (growth hormone-releasing hormone) analog administered by intramuscular injection; GH deficiency is established when the peak GH fails to exceed 10 ng/mL within 60 minutes of administration
C) Macimorelin is an orally administered SSTR2 (somatostatin receptor subtype 2) antagonist that stimulates GH secretion by blocking endogenous somatostatin inhibition; a peak GH below 5 ng/mL after oral dosing establishes the diagnosis of GH deficiency
D) Macimorelin is an intravenous insulin analog used in the same manner as insulin tolerance testing (ITT), inducing hypoglycemia as the physiological stimulus for GH release; it was developed to replace ITT by offering an equivalent hypoglycemic mechanism with fewer cardiovascular risks
E) Macimorelin is a subcutaneous IGF-1 (insulin-like growth factor-1) analog that stimulates GH secretion through long-loop negative feedback reversal; a peak GH below 3.5 ng/mL after subcutaneous injection establishes the diagnosis of GH deficiency
ANSWER: A
Rationale:
Macimorelin (Macrilen) is an orally bioavailable small molecule that acts as an agonist at GHSR-1a (growth hormone secretagogue receptor type 1a), the same receptor activated by endogenous ghrelin. It is FDA-approved for the diagnosis of adult GH deficiency. In the standard stimulation test protocol, a single oral dose of macimorelin 0.5 mg/kg (maximum 40 mg) is administered after an overnight fast; peak GH is measured at 30, 45, 60, and 90 minutes. A GH peak below 2.8 ng/mL (using liquid chromatography-tandem mass spectrometry immunoassay) establishes the diagnosis of GH deficiency in adults. The sensitivity and specificity of macimorelin are comparable to those of insulin tolerance testing (ITT), which has been the historical gold standard. The key advantage of macimorelin is that it does not carry the hypoglycemia risk of ITT, making it safer in patients with seizure disorders, cardiovascular disease, or older age, all of which are relative contraindications to ITT.
Option B: Option B is incorrect because macimorelin is oral, not injectable, and it acts via GHSR-1a, not GHRH-R; the diagnostic cutoff of 10 ng/mL described is not the validated threshold for this test.
Option C: Option C is incorrect because macimorelin is a GHSR-1a agonist, not an SSTR2 antagonist; it stimulates GH release by mimicking ghrelin signaling, not by blocking somatostatin; the diagnostic cutoff of 5 ng/mL described is also incorrect for this agent.
Option D: Option D is incorrect because macimorelin does not induce hypoglycemia; the absence of hypoglycemia risk is precisely its clinical advantage over ITT; macimorelin is an oral ghrelin receptor agonist that stimulates GH through an insulin-independent pathway.
Option E: Option E is incorrect because macimorelin is not an IGF-1 analog; it does not act through long-loop feedback; it is a ghrelin receptor agonist taken orally, not a subcutaneous IGF-1 preparation.
14. An endocrinologist plans to use a macimorelin stimulation test to evaluate a 38-year-old patient for adult GH (growth hormone) deficiency. During the medication review, the patient is noted to be taking rifampin for treatment of latent tuberculosis. The endocrinologist is concerned about a pharmacokinetic drug interaction that would compromise the reliability of the test result. What is the specific concern, and what is the recommended management?
A) Rifampin inhibits CYP3A4 (cytochrome P450 3A4) and would raise macimorelin plasma levels, producing a supratherapeutic GH stimulus and a falsely elevated GH peak that might cause the test to miss true GH deficiency; rifampin should be continued but macimorelin dose reduced by 50%
B) Rifampin induces P-glycoprotein (P-gp) efflux transporters in the gastrointestinal tract, reducing macimorelin absorption and raising its minimum detectable plasma concentration; this reduces the sensitivity of the GH assay but does not affect the diagnostic cutoff
C) Rifampin is a strong CYP3A4 (cytochrome P450 3A4) inducer; because macimorelin is a CYP3A4 substrate, rifampin accelerates macimorelin metabolism and reduces macimorelin plasma exposure, potentially producing a falsely low GH peak that could be interpreted as GH deficiency when the pituitary response is actually intact; rifampin should be discontinued before testing
D) Rifampin induces hepatic IGF-1 (insulin-like growth factor-1) production independently of GH by activating pregnane X receptor (PXR) signaling in hepatocytes; this raises baseline IGF-1 and suppresses pituitary GH secretion through negative feedback, reducing the GH response to macimorelin regardless of somatotroph function
E) Rifampin has no pharmacokinetic interaction with macimorelin because the ghrelin receptor (GHSR-1a) pathway is not regulated by CYP enzymes; the endocrinologist's concern is misplaced, and the test can proceed without modification
ANSWER: C
Rationale:
Macimorelin is metabolized by CYP3A4 (cytochrome P450 3A4) and is also a moderate inhibitor of P-glycoprotein (P-gp). Strong CYP3A4 inducers such as rifampin accelerate the metabolism of macimorelin, substantially reducing macimorelin plasma exposure (area under the curve and peak concentration). Lower macimorelin plasma levels produce a weaker GH secretagogue stimulus at the GHSR-1a receptor, resulting in a blunted GH peak. If a patient has adequate somatotroph function but is taking a strong CYP3A4 inducer, the GH peak may fall below the diagnostic cutoff of 2.8 ng/mL not because of true GH deficiency but because of inadequate macimorelin exposure — a false-positive diagnosis of GH deficiency. For this reason, strong CYP3A4 inducers (including rifampin, carbamazepine, phenytoin, and St. John's wort) should be discontinued before performing the macimorelin stimulation test.
Option A: Option A is incorrect because rifampin is a strong CYP3A4 inducer, not an inhibitor; it accelerates, not reduces, CYP3A4 metabolism; the consequence is reduced, not elevated, macimorelin exposure; reducing the dose would compound the problem.
Option B: Option B is incorrect because while rifampin does induce P-gp, the dominant pharmacokinetic interaction with macimorelin is CYP3A4 induction affecting systemic metabolism; the consequence is a falsely low GH peak from reduced drug exposure, not merely reduced assay sensitivity.
Option D: Option D is incorrect because rifampin does not induce hepatic IGF-1 production via PXR signaling; the IGF-1 axis is regulated by GH receptor signaling, not pregnane X receptor activation; this mechanism is fabricated.
Option E: Option E is incorrect because macimorelin is indeed a CYP3A4 substrate and the drug interaction with CYP3A4 inducers is real, clinically meaningful, and documented in the prescribing information; the test should not proceed without addressing this interaction.
15. A medical student asks why somatropin (recombinant human GH (growth hormone)) must be given by subcutaneous injection every day rather than orally, since the plasma half-life of somatropin itself is only about 2 to 4 hours. The attending explains both the route-of-administration rationale and the pharmacodynamic basis for once-daily dosing. Which of the following correctly addresses both questions?
A) Somatropin cannot be given orally because it is a large molecule that fails to cross the intestinal brush-border membrane by passive diffusion; it is given once daily because peak GH concentrations persist for 24 hours after subcutaneous injection due to slow release from subcutaneous fat depots
B) Somatropin cannot be given orally because the gastrointestinal tract lacks the specific peptide transporter required for GH absorption; it is given once daily because the hepatic first-pass effect degrades somatropin very slowly after subcutaneous injection, effectively extending its plasma half-life to 24 hours
C) Somatropin cannot be given orally because it would be excessively absorbed in the upper gastrointestinal tract, producing toxic peak plasma levels; it is given by subcutaneous injection to slow absorption and achieve a pharmacokinetic profile that mimics physiological nocturnal GH pulsatility
D) Somatropin cannot be given orally because its high molecular weight prevents intestinal absorption by any route, and once-daily dosing is justified because somatropin has a plasma half-life of 24 hours by the subcutaneous route, allowing stable trough levels
E) Somatropin is a 191-amino acid peptide susceptible to enzymatic degradation by gastrointestinal proteases, precluding oral bioavailability; once-daily dosing is pharmacodynamically justified by IGF-1 (insulin-like growth factor-1), which is induced by each somatropin dose and has a circulating half-life of approximately 12 to 15 hours, providing sustained biological effect well beyond the 2 to 4-hour plasma half-life of somatropin itself
ANSWER: E
Rationale:
Somatropin is a 191-amino acid single-chain polypeptide that, like all protein hormones administered therapeutically, cannot be taken orally because gastrointestinal proteases (pepsin, trypsin, chymotrypsin, and other peptidases) rapidly degrade peptide bonds in the gastrointestinal tract before absorption can occur. All approved somatropin formulations are therefore administered parenterally, nearly exclusively by subcutaneous injection, with bioavailability of approximately 70 to 90% after SC injection. The plasma elimination half-life of somatropin itself is short, approximately 2 to 4 hours, which might seem to preclude once-daily dosing. However, the pharmacodynamic justification for once-daily dosing lies in IGF-1 (insulin-like growth factor-1): each dose of somatropin induces hepatic IGF-1 synthesis, and circulating IGF-1 — which is bound to IGFBP-3 (IGF-binding protein-3) in a ternary complex — has a plasma half-life of approximately 12 to 15 hours. Because IGF-1 mediates most of the growth-promoting and metabolic effects of GH, the sustained IGF-1 elevation provides biological activity well beyond the window of somatropin itself, supporting once-daily administration.
Option A: Option A is incorrect because the barrier to oral delivery is proteolytic degradation, not failure to cross via passive diffusion; and somatropin peak plasma concentrations do not persist for 24 hours — the plasma half-life is 2 to 4 hours; sustained effect is mediated through IGF-1, not prolonged somatropin levels.
Option B: Option B is incorrect because there is no specific peptide transporter required for GH and the issue is enzymatic degradation in the GI lumen, not transporter absence; and the hepatic first-pass metabolism argument does not explain once-daily dosing — the pharmacodynamic bridge is IGF-1.
Option C: Option C is incorrect because somatropin is not bioavailable orally at all — it is destroyed, not excessively absorbed; the rationale for SC dosing is bioavailability after proteolytic degradation prevention, not slowing absorption.
Option D: Option D is incorrect because somatropin does not have a 24-hour plasma half-life by the subcutaneous route; the SC half-life remains approximately 2 to 4 hours; once-daily dosing is justified by IGF-1 kinetics, not extended somatropin plasma half-life.
16. A 35-year-old patient with panhypopituitarism is on stable hydrocortisone replacement at 15 mg in the morning and 5 mg at noon. She is now starting somatropin (recombinant GH (growth hormone)) replacement for confirmed adult GH deficiency. Three weeks after initiating somatropin, she presents with fatigue, nausea, anorexia, and a weight loss of 3 kg. Laboratory evaluation reveals a low morning cortisol. Which pharmacological mechanism best explains this clinical presentation?
A) Somatropin activates the mineralocorticoid receptor and promotes renal sodium excretion, reducing extracellular fluid volume and precipitating an adrenal crisis-like state through volume depletion rather than through cortisol deficiency
B) Somatropin induces CYP3A4 (cytochrome P450 3A4) expression, which accelerates the metabolism and clearance of hydrocortisone; in a patient on a borderline replacement dose, increased glucocorticoid clearance reduces plasma cortisol concentrations below the physiological requirement, unmasking adrenal insufficiency
C) Somatropin directly suppresses ACTH (adrenocorticotropic hormone) secretion from the anterior pituitary through IGF-1 (insulin-like growth factor-1) negative feedback on corticotrophs, reducing adrenal cortisol output independently of hydrocortisone dose
D) Somatropin competitively displaces hydrocortisone from corticosteroid-binding globulin (CBG), reducing the bound fraction and increasing the free fraction of hydrocortisone available for renal clearance, thereby shortening the effective duration of the replacement dose
E) Somatropin stimulates peripheral cortisol conversion to cortisone through 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) at the kidney, reducing systemic cortisol exposure and precipitating insufficiency; dose adjustment of fludrocortisone rather than hydrocortisone is the appropriate correction
ANSWER: B
Rationale:
Somatropin (GH replacement) significantly induces CYP3A4 (cytochrome P450 3A4) and CYP2C19 (cytochrome P450 2C19) expression. CYP3A4 induction accelerates the hepatic conversion of cortisol to inactive cortisone and increases the peripheral clearance of synthetic glucocorticoids including hydrocortisone and prednisone. In a patient with central adrenal insufficiency who is on a hydrocortisone replacement dose that was appropriate before GH initiation, CYP3A4 induction by somatropin may render that dose inadequate by accelerating glucocorticoid clearance. The result is unmasking of adrenal insufficiency — clinically presenting as fatigue, nausea, anorexia, and weight loss, as in this patient. Before starting GH replacement, the HPA (hypothalamic-pituitary-adrenal) axis should be assessed and glucocorticoid replacement must be confirmed adequate. After starting, hydrocortisone doses typically require upward adjustment of approximately 20 to 30%. This interaction does not apply to patients with intact adrenal function at physiological cortisol levels.
Option A: Option A is incorrect because somatropin promotes sodium retention and water retention (not excretion) through renal tubular effects — a peripheral edema-promoting rather than volume-depleting action; the clinical presentation in this patient reflects cortisol deficiency, not volume depletion from renal sodium loss.
Option C: Option C is incorrect because somatropin does not directly suppress ACTH secretion; this patient has pre-existing central adrenal insufficiency from panhypopituitarism and is on replacement hydrocortisone; IGF-1-mediated ACTH suppression at the pituitary is not the mechanism of reduced plasma cortisol in this clinical scenario.
Option D: Option D is incorrect because somatropin does not displace hydrocortisone from corticosteroid-binding globulin; this is not a recognized pharmacokinetic interaction; CBG displacement is not the established mechanism of this drug interaction.
Option E: Option E is incorrect because the dominant mechanism of reduced glucocorticoid exposure here is CYP3A4 induction with accelerated hepatic clearance, not selective 11β-HSD2-mediated renal conversion; and fludrocortisone adjustment is not the appropriate response — the glucocorticoid (hydrocortisone) dose requires adjustment, not the mineralocorticoid.
17. An intensivist is asked whether somatropin (recombinant GH (growth hormone)) replacement should be continued in a 58-year-old patient with known adult GH deficiency who has been admitted to the ICU (intensive care unit) with septic shock and multi-organ dysfunction. The patient has been on somatropin for 3 years with good biochemical control. What is the correct management, and what is the pharmacological basis for the decision?
A) Somatropin should be continued without interruption because abrupt discontinuation in a GH-deficient patient precipitates acute adrenal crisis by reversing CYP3A4 induction and causing cortisol accumulation above physiological levels, which suppresses the HPA (hypothalamic-pituitary-adrenal) axis acutely
B) Somatropin should be dose-reduced by 50% during acute illness because the metabolic stress of critical illness independently raises endogenous GH levels, and continuation of full replacement doses may produce pharmacological GH excess and worsen insulin resistance during the ICU admission
C) Somatropin replacement is not affected by acute illness and should be maintained; the growth-promoting and anabolic effects of GH are beneficial in critically ill patients, and suspension of replacement therapy increases mortality by accelerating lean muscle catabolism in the ICU
D) Somatropin should be discontinued in this patient; acute critical illness is a contraindication to somatropin therapy based on evidence from two pivotal studies showing increased mortality in critically ill patients receiving pharmacological doses of GH; the drug should be restarted after recovery from the acute illness
E) Somatropin should be switched to its prodrug, sermorelin, during critical illness because the shorter-acting GHRH (growth hormone-releasing hormone) analog provides lower IGF-1 (insulin-like growth factor-1) stimulation and is safer in the ICU setting than direct GH administration
ANSWER: D
Rationale:
Somatropin has two absolute contraindications that apply regardless of the indication for which the patient is being treated: active malignancy and acute critical illness. The contraindication in critical illness is based on evidence from two pivotal controlled trials in which critically ill adults receiving pharmacological doses of somatropin (far above physiological replacement doses) showed substantially increased mortality compared with placebo-treated controls. Although these trials used pharmacological rather than replacement doses, the contraindication has been extended to include all patients with acute critical illness, including those on established replacement therapy for adult GH deficiency. The drug should be discontinued when a patient is admitted with acute critical illness and restarted after recovery. This is a clear FDA-label contraindication.
Option A: Option A is incorrect because discontinuing somatropin does not precipitate adrenal crisis; the CYP3A4 induction from GH does mean that glucocorticoid dosing may need re-evaluation upon stopping, but the risk runs in the opposite direction — stopping GH reduces CYP3A4 activity and may allow glucocorticoid accumulation relative to the previously titrated replacement dose, requiring downward adjustment, not upward.
Option B: Option B is incorrect because the recommendation is not dose reduction but discontinuation; this is an absolute contraindication, not a dose-adjustment indication; the logic of reducing rather than stopping does not reflect the label guidance or clinical evidence.
Option C: Option C is incorrect because the clinical evidence directly contradicts the premise that GH is beneficial in critically ill patients; the pivotal trials showed increased mortality, not decreased, in GH-treated critically ill adults, which is why the contraindication exists.
Option E: Option E is incorrect because there is no approved prodrug form of GH and sermorelin is not established as a safer alternative in critical illness; the solution is drug discontinuation, not substitution.
18. An endocrinology fellow is explaining the mechanism of pegvisomant to a medical student. She emphasizes that pegvisomant acts through a fundamentally different mechanism than somatostatin receptor analogs (SSAs) and that this difference has direct implications for monitoring and for pituitary tumor behavior during therapy. Which of the following correctly describes pegvisomant's mechanism of action?
A) Pegvisomant is a genetically engineered GH (growth hormone) receptor antagonist derived from native GH with amino acid substitutions that preserve high-affinity GHR (GH receptor) binding but prevent receptor dimerization and JAK2-STAT5 (Janus kinase 2-signal transducer and activator of transcription 5) activation; it acts entirely at the peripheral receptor level, leaving pituitary GH secretion unsuppressed and typically elevated during therapy
B) Pegvisomant is a modified somatostatin analog with PEGylation (polyethylene glycol conjugation) added to extend its half-life; it acts at SSTR2 and SSTR5 on pituitary somatotrophs to suppress GH secretion, and its peripheral effects are mediated indirectly through GH suppression rather than through direct receptor antagonism
C) Pegvisomant binds the GHRH receptor (GHRH-R) on pituitary somatotrophs as a competitive antagonist, blocking GHRH-stimulated GH synthesis and secretion; because it acts at the pituitary level, serum GH declines during therapy and can be used as a monitoring marker
D) Pegvisomant is a monoclonal antibody that neutralizes circulating GH by forming immune complexes that are rapidly cleared by the reticuloendothelial system; because GH is removed from circulation before reaching its receptor, both GH and IGF-1 (insulin-like growth factor-1) levels fall during therapy
E) Pegvisomant binds IGF-1 (insulin-like growth factor-1) in the circulation and prevents its binding to the IGF-1 receptor (IGF-1R) at peripheral tissues; by blocking IGF-1 at the target-cell level, it prevents downstream growth-promoting signaling without affecting GH secretion from the pituitary
ANSWER: A
Rationale:
Pegvisomant (Somavert) is a genetically engineered GH receptor antagonist structurally derived from native GH but modified with specific amino acid substitutions that prevent receptor dimerization and signal transduction while preserving high-affinity GHR binding. Native GH activates its receptor by binding one GHR subunit and inducing dimerization of two GHR subunits, which then activates JAK2 (Janus kinase 2), leading to STAT5 (signal transducer and activator of transcription 5) phosphorylation and downstream signaling. Pegvisomant binds GHR but cannot support productive dimerization, functioning as a competitive antagonist at the receptor. Critically, pegvisomant acts entirely at the peripheral receptor level — it does not suppress pituitary GH secretion. Because IGF-1 (insulin-like growth factor-1) normally exerts negative feedback on pituitary somatotrophs, and because pegvisomant blocks the IGF-1-generating pathway, IGF-1 levels fall during therapy while GH secretion from the pituitary is disinhibited and typically rises. This makes serum GH unreliable and potentially misleading as a monitoring marker; only serum IGF-1 reflects treatment response.
Option B: Option B is incorrect because pegvisomant is not a somatostatin analog; its structural basis is native GH, not somatostatin; it acts at the peripheral GH receptor, not at pituitary SSTR subtypes; the PEGylation in its name refers to its drug design, not a modified SSA.
Option C: Option C is incorrect because pegvisomant acts at the peripheral GH receptor (GHR) on target cells, not at the pituitary GHRH receptor; GH secretion rises during pegvisomant therapy, and GH is specifically not a useful monitoring marker.
Option D: Option D is incorrect because pegvisomant is not a monoclonal antibody and does not neutralize GH by immune complex formation; it is a receptor-level antagonist derived from a modified GH molecule, and both GH levels and IGF-1 levels behave differently — GH rises while IGF-1 falls.
Option E: Option E is incorrect because pegvisomant blocks GHR signaling at the receptor level in target cells, not circulating IGF-1 binding to the IGF-1 receptor; it prevents IGF-1 generation by blocking GH receptor signaling, rather than blocking IGF-1 action downstream.
19. A patient with acromegaly is started on pegvisomant after failing to achieve biochemical control on maximum-dose lanreotide. At the 3-month follow-up visit, the laboratory results show a serum GH of 28 ng/mL (markedly elevated) and a serum IGF-1 (insulin-like growth factor-1) in the normal age-adjusted range. The patient feels significantly better. How should these laboratory results be interpreted, and what is the appropriate clinical action?
A) The elevated serum GH indicates treatment failure; pegvisomant should be discontinued immediately and the patient switched to a higher-dose somatostatin receptor analog (SSA), because a serum GH above 1 ng/mL confirms that the pituitary adenoma is secreting GH at a rate that exceeds the drug's receptor antagonism capacity
B) The elevated serum GH and normal IGF-1 are contradictory results that indicate laboratory error; both values must be rechecked before a clinical decision can be made, because serum GH and IGF-1 should move in the same direction during any effective acromegaly therapy
C) This is the expected monitoring pattern with pegvisomant; serum GH rises during therapy because IGF-1 suppression removes negative feedback on pituitary somatotrophs, disinhibiting GH secretion; serum IGF-1 is the sole reliable monitoring marker for pegvisomant response, and a normal IGF-1 indicates adequate biochemical control; no dose change is indicated
D) The elevated serum GH indicates that pegvisomant has caused a rebound hypersecretion of GH from the pituitary tumor due to loss of SSA-mediated SSTR2 suppression; the patient should be immediately restarted on an SSA in combination with pegvisomant to control tumor GH output
E) The elevated serum GH indicates progressive pituitary tumor growth in the absence of any GH-suppressing therapy; urgent pituitary MRI (magnetic resonance imaging) should be performed to evaluate tumor size before the next dose of pegvisomant is administered
ANSWER: C
Rationale:
The pattern of elevated serum GH with normal serum IGF-1 during pegvisomant therapy is expected, diagnostically correct, and does not represent treatment failure. Pegvisomant acts as a peripheral GH receptor (GHR) antagonist, blocking GHR dimerization and JAK2-STAT5 (Janus kinase 2-signal transducer and activator of transcription 5) signaling at target tissues including the liver. Because hepatic IGF-1 production is blocked at the receptor level, serum IGF-1 falls toward the normal range during effective therapy. However, the pituitary somatotroph is still secreting GH — pegvisomant does not suppress pituitary GH output. Furthermore, because IGF-1 normally provides long-loop negative feedback to suppress GH secretion, the fall in IGF-1 during pegvisomant therapy removes this brake, and pituitary GH secretion is disinhibited, causing serum GH to rise. Serum GH is not a useful monitoring marker during pegvisomant therapy and should not be used to assess adequacy of treatment; serum IGF-1 is the sole reliable monitoring endpoint. A normal age- and sex-adjusted IGF-1 indicates adequate biochemical control.
Option A: Option A is incorrect because elevated serum GH during pegvisomant therapy is mechanistically expected and does not indicate treatment failure; applying the standard SSA monitoring threshold of GH above 1 ng/mL is inappropriate in this context because the mechanism of action and appropriate monitoring markers differ fundamentally.
Option B: Option B is incorrect because GH and IGF-1 do not move in the same direction during pegvisomant therapy; this is the pharmacologically predicted dissociation — the two values moving in opposite directions is characteristic of pegvisomant's mechanism, not a laboratory error.
Option D: Option D is incorrect because elevated GH during pegvisomant therapy is not a rebound phenomenon or evidence of loss of SSTR2 control; it reflects physiological disinhibition of somatotroph GH secretion due to falling IGF-1 negative feedback, not tumor escape from drug effect.
Option E: Option E is incorrect because elevated GH alone during pegvisomant therapy does not indicate tumor growth; annual pituitary MRI is recommended as a surveillance protocol because pegvisomant does not reduce tumor volume, but urgent imaging is not indicated solely on the basis of an elevated GH in a patient who otherwise has normal IGF-1 and clinical improvement.
20. A patient with acromegaly on pegvisomant monotherapy has a routine laboratory check at 6 months. Her ALT (alanine aminotransferase) is reported at 6.2 times the upper limit of normal (ULN), with AST (aspartate aminotransferase) at 5.8 times ULN. She is asymptomatic and her serum bilirubin is normal. What is the correct clinical action based on pegvisomant's hepatotoxicity monitoring protocol?
A) No dose change is required at this level of enzyme elevation; monitoring should continue monthly, and pegvisomant should only be discontinued if AST or ALT exceeds 10 times ULN or if jaundice develops
B) Pegvisomant should be dose-reduced by 50% and liver function tests (LFTs) repeated in 4 weeks; discontinuation is reserved for patients with concurrent symptomatic hepatitis or coagulopathy regardless of the degree of enzyme elevation
C) The ALT and AST elevation at this level is an expected and benign consequence of pegvisomant-induced normalization of IGF-1 (insulin-like growth factor-1), which resolves acromegaly-related hepatic steatosis; no change in management is needed and routine 6-month monitoring can continue
D) More frequent liver function test monitoring should be initiated, with measurements every 2 to 4 weeks, because an elevation of three or more times ULN requires closer surveillance; pegvisomant does not need to be discontinued unless AST or ALT exceeds 10 times ULN
E) Pegvisomant should be discontinued because an ALT or AST elevation exceeding five times ULN requires drug discontinuation pending further hepatological investigation; this threshold is specified in the pegvisomant monitoring protocol
ANSWER: E
Rationale:
Hepatotoxicity is the most important safety concern with pegvisomant. Clinically significant elevations of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) occur in approximately 5 to 8% of patients on pegvisomant therapy. The monitoring protocol specifies: liver function tests (ALT, AST, bilirubin) at baseline before initiating pegvisomant; thereafter every 6 months during therapy. If AST or ALT exceeds three times ULN, monitoring frequency should increase. If AST or ALT exceeds five times ULN, pegvisomant must be discontinued pending hepatological investigation. In this patient, both ALT (6.2× ULN) and AST (5.8× ULN) exceed the five-times-ULN threshold, and drug discontinuation is required regardless of the absence of symptoms or jaundice.
Option A: Option A is incorrect because the threshold for discontinuation is five times ULN, not ten times ULN; asymptomatic hepatotoxicity at the current level does require drug discontinuation; continuing treatment with monthly monitoring alone is not compliant with the monitoring protocol.
Option B: Option B is incorrect because dose reduction is not the appropriate response when the five-times-ULN threshold has been exceeded; the protocol requires discontinuation, not dose reduction, at this level of enzyme elevation.
Option C: Option C is incorrect because while pegvisomant can improve acromegaly-related hepatic steatosis, enzyme elevations exceeding five times ULN are not explained as benign normalization of steatosis; they represent a hepatotoxicity signal requiring drug discontinuation and investigation.
Option D: Option D is incorrect because a three-times-ULN elevation warrants more frequent monitoring, but this patient's enzyme elevation exceeds five times ULN — a higher threshold that triggers discontinuation, not merely intensified monitoring.
21. An endocrinologist is titrating somatropin (recombinant GH (growth hormone)) replacement in two female patients with adult GH deficiency, both of the same age with similar clinical presentations. Patient A is on oral estrogen (conjugated equine estrogen 0.625 mg daily) for menopausal hormone therapy, while Patient B is on transdermal estradiol patches. Despite identical somatropin doses, Patient A's serum IGF-1 (insulin-like growth factor-1) remains consistently below the target range while Patient B's IGF-1 is within range. Which pharmacodynamic mechanism explains why Patient A requires a higher somatropin dose than Patient B to achieve equivalent IGF-1 responses?
A) Oral estrogen induces CYP3A4 (cytochrome P450 3A4) in the intestinal wall, increasing first-pass metabolism of subcutaneous somatropin and reducing its systemic bioavailability; transdermal estradiol avoids intestinal first-pass exposure and therefore does not affect somatropin bioavailability
B) Oral estrogen undergoes significant first-pass portal circulation exposure, delivering high concentrations of estrogen to the liver; hepatic estrogen suppresses GH receptor (GHR) signaling in hepatocytes, reducing hepatic IGF-1 production in response to any given somatropin dose; transdermal estradiol avoids the portal first-pass effect and does not significantly suppress hepatic IGF-1 production, so the same somatropin dose produces a normal IGF-1 response
C) Oral estrogen reduces GH pulsatility by suppressing hypothalamic GHRH (growth hormone-releasing hormone) secretion through estrogen receptor action in the arcuate nucleus; transdermal estradiol has the same effect but at lower magnitude, explaining the smaller dose requirement in Patient B
D) Oral estrogen increases the renal clearance of IGF-1 by upregulating the glomerular IGF-1 filtration rate through estrogen receptor-mediated effects on the proximal tubule; transdermal estradiol does not increase IGF-1 renal clearance, and therefore less IGF-1 is lost in the urine with transdermal therapy
E) Oral estrogen directly inhibits somatropin binding to GHR by allosteric modification of the receptor; this mechanism is unique to oral estrogen because first-pass hepatic conversion produces an estriol metabolite that is the actual allosteric inhibitor; transdermal estradiol is not converted to this metabolite at the liver
ANSWER: B
Rationale:
The route of estrogen administration has a clinically important effect on hepatic IGF-1 production and thus on somatropin dose requirements in women on GH replacement therapy. Oral estrogen is absorbed from the gastrointestinal tract and delivered at high concentrations to the liver via the portal circulation before reaching systemic circulation — a pharmacokinetic phenomenon called the first-pass portal effect. High hepatic estrogen concentrations suppress GH receptor (GHR) signaling in hepatocytes, reducing hepatic IGF-1 production in response to exogenous somatropin. As a result, women on oral estrogen require substantially higher somatropin doses to achieve target IGF-1 concentrations compared with women on transdermal estradiol or men. Transdermal estradiol is absorbed through the skin and enters the systemic circulation directly, bypassing portal first-pass delivery to the liver; hepatic estrogen exposure is much lower, and GHR-mediated IGF-1 production is not significantly suppressed. This pharmacodynamic sex difference has direct dose-adjustment implications in clinical practice and is documented in GH replacement guidelines.
Option A: Option A is incorrect because somatropin is administered subcutaneously and does not undergo intestinal first-pass metabolism; CYP3A4 induction in the intestinal wall is irrelevant to parenteral somatropin bioavailability; the pharmacodynamic effect operates at the hepatic IGF-1 production level, not at somatropin absorption.
Option C: Option C is incorrect because the mechanism is not suppression of hypothalamic GHRH secretion; in patients already receiving exogenous somatropin replacement, hypothalamic GHRH regulation is not the limiting step; the relevant interaction is at the hepatocyte GHR-IGF-1 axis.
Option D: Option D is incorrect because estrogen does not increase IGF-1 renal clearance through proximal tubule effects; this mechanism is fabricated and does not reflect established pharmacodynamics of estrogen-GH axis interactions.
Option E: Option E is incorrect because no estriol allosteric inhibitor of GHR exists; the mechanism of oral estrogen's effect on IGF-1 is portal first-pass suppression of hepatic GHR signaling, not allosteric receptor modification.
22. A renal transplant recipient who is maintained on cyclosporine immunosuppression is diagnosed with a GH-secreting pituitary adenoma (acromegaly). After incomplete surgical resection, octreotide LAR is initiated for medical management of residual GH hypersecretion. The prescribing physician asks what monitoring is required because of a potential drug interaction between octreotide and cyclosporine. Which of the following correctly describes this interaction and its clinical implication?
A) Octreotide inhibits CYP3A4 (cytochrome P450 3A4) in the liver, reducing cyclosporine metabolism and raising cyclosporine plasma levels; cyclosporine trough levels should be monitored after initiating octreotide because of the risk of nephrotoxicity from supratherapeutic cyclosporine concentrations
B) Octreotide competes with cyclosporine for P-glycoprotein (P-gp) efflux transport in the kidney, reducing cyclosporine renal excretion and raising its plasma concentrations; reducing the cyclosporine dose by 25% at the time of octreotide initiation is recommended prophylactically
C) There is no clinically significant interaction between octreotide and cyclosporine; somatostatin receptor analogs (SSAs) do not affect cyclosporine pharmacokinetics because they act at a receptor level that is unrelated to cytochrome P450 enzymes or gastrointestinal drug transport
D) Somatostatin receptor analogs (SSAs) reduce gastrointestinal absorption of cyclosporine by inhibiting intestinal motility and secretion; decreased cyclosporine absorption can lower plasma trough concentrations and precipitate acute rejection in transplant recipients; cyclosporine trough levels must be monitored after initiating SSA therapy
E) Octreotide raises cyclosporine plasma levels by displacing it from alpha-1-acid glycoprotein (AAG) binding sites in the plasma; the resulting increase in free cyclosporine fraction is pharmacodynamically equivalent to a dose increase and requires a prophylactic reduction in the cyclosporine nominal dose
ANSWER: D
Rationale:
Somatostatin receptor analogs including octreotide and lanreotide reduce the gastrointestinal absorption of cyclosporine. The mechanism involves SSA-mediated inhibition of intestinal motility and reduction of gastrointestinal secretion, which impairs the absorptive processes that cyclosporine depends on for oral bioavailability. Cyclosporine is already a drug with highly variable and relatively low oral bioavailability, and further reduction in absorption by SSAs can produce clinically significant decreases in plasma trough concentrations. In a transplant recipient, sub-therapeutic cyclosporine levels raise the risk of acute allograft rejection, which is a serious and potentially graft-threatening complication. Therefore, cyclosporine trough levels must be monitored after initiating any SSA in a transplant patient, and the cyclosporine dose may require upward adjustment.
Option A: Option A is incorrect because octreotide does not inhibit CYP3A4; the SSA-cyclosporine interaction is a gastrointestinal absorption interaction, not a CYP3A4-mediated metabolism interaction; the direction of the interaction is reduced, not elevated, cyclosporine levels, the opposite of the claim that octreotide raises cyclosporine concentrations through CYP3A4 inhibition.
Option B: Option B is incorrect because the interaction is not mediated through P-gp competition at the kidney and does not raise cyclosporine levels; it reduces cyclosporine absorption via gastrointestinal motility inhibition; prophylactic dose reduction would be the wrong response to a drug interaction that reduces, rather than raises, cyclosporine exposure.
Option C: Option C is incorrect because there is a clinically meaningful interaction between SSAs and cyclosporine; characterizing it as absent is pharmacologically incorrect and potentially dangerous in a transplant setting; monitoring of cyclosporine levels is mandatory in this clinical scenario.
Option E: Option E is incorrect because octreotide does not displace cyclosporine from alpha-1-acid glycoprotein; protein binding competition is not the mechanism of this interaction; the actual mechanism is impaired gastrointestinal absorption due to SSA effects on intestinal motility and secretion.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.